Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.

Department of Radiology, University of California, San Francisco, USA.
Alzheimer's & dementia: the journal of the Alzheimer's Association (Impact Factor: 12.41). 09/2011; 7(5):514-20. DOI: 10.1016/j.jalz.2010.12.010
Source: PubMed


The majority of studies relating amyloid pathology with brain volumes have been cross-sectional. Apolipoprotein ɛ4 (APOE ɛ4), a genetic risk factor for Alzheimer's disease, is also known to be associated with hippocampal volume loss. No studies have considered the effects of amyloid pathology and APOE ɛ4 together on longitudinal volume loss.
We evaluated whether an abnormal level of cerebrospinal fluid beta-amyloid (CSF Aβ) and APOE ɛ4 carrier status were independently associated with greater hippocampal volume loss over 1 year. We then assessed whether APOE ɛ4 status and CSF Aβ acted synergistically, testing the significance of an interaction term in the regression analysis. We included 297 participants: 77 cognitively normal, 144 with mild cognitive impairment (MCI), and 76 with Alzheimer's disease.
An abnormal CSF Aβ level was found to be associated with greater hippocampal volume loss over 1 year in each group. APOE ɛ4 was associated with hippocampal volume loss only in the cognitively normal and MCI groups. APOE ɛ4 carriers with abnormal CSF Aβ in the MCI group acted synergistically to produce disproportionately greater volume loss than noncarriers.
Baseline CSF Aβ predicts progression of hippocampal volume loss. APOE ɛ4 carrier status amplifies the degree of neurodegeneration in MCI. Understanding the effect of interactions between genetic risk and amyloid pathology will be important in clinical trials and our understanding of the disease process.

Download full-text


Available from: Paul Thompson,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medial temporal lobe atrophy (MTA) and cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD) pathology may aid the early detection of AD in mild cognitive impairment (MCI). However, the relationship between structural and pathological markers is not well understood. Furthermore, while posterior atrophy (PA) is well recognized in AD, its value in predicting conversion from late-onset amnestic MCI to AD is unclear. In this study we used visual ratings of MTA and PA to assess their value in predicting conversion to AD in 394 MCI patients. The relationship of atrophy patterns with CSF Aβ1-42, tau, and p-tau(181) was further investigated in 114 controls, 192 MCI, and 99 AD patients. There was a strong association of MTA ratings with conversion to AD (p < 0.001), with a weaker association for PA ratings (p = 0.047). Specific associations between visual ratings and CSF biomarkers were found; MTA was associated with lower levels of Aβ1-42 in MCI, while PA was associated with elevated levels of tau in MCI and AD, which may reflect widespread neuronal loss including posterior regions. These findings suggest both that posterior atrophy may predict conversion to AD in late-onset MCI, and that there may be differential relationships between CSF biomarkers and regional atrophy patterns.
    Neurobiology of aging 04/2012; 34(1). DOI:10.1016/j.neurobiolaging.2012.03.010 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the author's clinical activity at three institutes : Kyoto University Hospital (Kyoto 1965-1969, 1977-1985), National Cardiovascular Center NCVC (Osaka 1986-1992) and Zurich University Hospital (Zurich 1970-1976, 1993-2007), He has experienced (underlined periods) working with PET scan and SPECT in relation to microsurgical treatment. The following describes how and for what the author has been engaged in this regard. 1. As preparation for the work with PET, SPECT with a rotating gamma camera was used to know blood distribution with the use of Kr-81m infusion from a selectively located catheter in the ICA, ECA or VA, e.g. to know the flow distribution of a newly constructed EC-IC bypass, which was quite separated from and not mixed up with that of already functioning inherent collaterals (Fig. 1). 2. With the use of inhalation PET scan (15O labelled CO2 and O2 inhalation and 15O CO inhalation) basic knowledge of hemodynamics of MMD was acquired (Fig. 2) 3. With the use of H215 O-PET scan with DiamoxR loading, indication for and effectiveness of EC-IC bypass surgery for occlusive cerebrovascular disease (atherosclerosis (anterior circulation (Fig. 5), posterior circulation (Fig. 6, 7)), MMD (Fig. 9), congenital disease (Fig. 8) have been settled or demonstrated. 4. In epileptic seizures, interictally or intraictally, the active locus has been identified by the use of FDG-PET, flumazenil-PET, H 2 15 O or 13 NH 3-PET respectively (Fig. 12). In this relation, selective Wada test with the use of Tc-99 m-ECD selective infusion together with Amytal R through a catheter inserted selectively into the anterior choroidal artery is an important preoperative test for the SAHE (Fig. 13). 5. FDG-PET and/or tyrosine PET supply important clues concerning appropriate surgical treatment strategy, and also for intractable glioblastoma or high grade glioma, so that in combination with radiotherapy and chemotherapy one may expect more excellent long term outcome with good quality of life (Fig. 16, 17). Furthermore, there must be cases with dementia in which some revascularization procedure might be of help, for which FDG-and H 2 15O-PET could be helpful for differential diagnosis and indication of surgery (Fig. 18).
    No shinkei geka. Neurological surgery 09/2012; 40(9):823-46. · 0.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals carrying the *E4 allele of the apolipoprotein E gene (APOE) are at increased risk of developing Alzheimer's disease (AD). However, the biological mechanisms underlying this association are still unclear because of the complexity of the pathological processes that cause AD. Furthermore, the effect of APOE genotype on development, maintenance and aging of the normal brain is poorly understood because of the strong bias towards studying disease associations. In vivo techniques such as neuroimaging and cognitive testing offer valuable insights into the effects of APOE genotype on brain structure and function in healthy and clinical populations. We review the evidence from in vivo studies that APOE *E4, in addition to increasing the chance of age-related pathological events, is associated with age-independent non-pathological changes in brain physiology, some of which make the brain less resilient to neurodegenerative processes. We argue that the interaction between the APOE-dependent non-pathological vulnerabilities and age-related pathological changes is one mechanism that can trigger neurodegeneration, resulting in AD and other complex phenotypes.
    Neuroscience & Biobehavioral Reviews 05/2013; 37(8). DOI:10.1016/j.neubiorev.2013.05.006 · 8.80 Impact Factor
Show more